- Home
- IPGP vs NAMS Comparison
IPGP vs NAMS Comparison
Compare IPGP & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPGP
- NAMS
- Stock Information
- Founded
- IPGP 1990
- NAMS 2019
- Country
- IPGP United States
- NAMS Netherlands
- Employees
- IPGP N/A
- NAMS N/A
- Industry
- IPGP Semiconductors
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- IPGP Technology
- NAMS Health Care
- Exchange
- IPGP Nasdaq
- NAMS Nasdaq
- Market Cap
- IPGP 3.3B
- NAMS 2.7B
- IPO Year
- IPGP 2006
- NAMS N/A
- Fundamental
- Price
- IPGP $63.17
- NAMS $18.57
- Analyst Decision
- IPGP Hold
- NAMS Strong Buy
- Analyst Count
- IPGP 6
- NAMS 7
- Target Price
- IPGP $89.33
- NAMS $41.33
- AVG Volume (30 Days)
- IPGP 249.4K
- NAMS 646.5K
- Earning Date
- IPGP 02-11-2025
- NAMS 03-04-2025
- Dividend Yield
- IPGP N/A
- NAMS N/A
- EPS Growth
- IPGP N/A
- NAMS N/A
- EPS
- IPGP N/A
- NAMS N/A
- Revenue
- IPGP $977,134,000.00
- NAMS $33,594,000.00
- Revenue This Year
- IPGP $2.34
- NAMS $131.53
- Revenue Next Year
- IPGP $6.80
- NAMS N/A
- P/E Ratio
- IPGP N/A
- NAMS N/A
- Revenue Growth
- IPGP N/A
- NAMS 78.77
- 52 Week Low
- IPGP $60.72
- NAMS $15.19
- 52 Week High
- IPGP $92.21
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- IPGP 32.02
- NAMS 29.65
- Support Level
- IPGP $60.72
- NAMS $18.88
- Resistance Level
- IPGP $65.88
- NAMS $20.46
- Average True Range (ATR)
- IPGP 2.81
- NAMS 1.11
- MACD
- IPGP -0.36
- NAMS -0.09
- Stochastic Oscillator
- IPGP 21.29
- NAMS 5.84
About IPGP IPG Photonics Corporation
IPG Photonics Corp is a vertically integrated developer and manufacturer of high-performance fiber lasers, fiber amplifiers, and diode lasers, which are used in diverse applications in the manufacturing, automotive, industrial, aerospace, semiconductor, and consumer end markets. A large majority of the firm's revenue is derived from materials processing applications for fiber lasers, including cutting and welding, marking and engraving, and micro-processing. The company generates a majority of its revenue from China and also has its presence in North America, Japan, Germany, and other markets.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.